<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Panitumumab is an anti-EGF receptor (EGFR) antibody approved for use in treatment of chemotherapy-refractory <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> lacking K-<z:mp ids='MP_0011356'>RAS</z:mp> mutations </plain></SENT>
<SENT sid="1" pm="."><plain>Despite overall response rates approximating 10%, no marker predictive of clinical benefit has been identified </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a chemotherapy-refractory patient whose clinical condition necessitated rapid identification of an effective agent in whom we used (18)F-fluorodeoxyglucose-<z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (FDG-PET)/computed tomographic scanning 48 hours after an initial dose of panitumumab to document a pharmacodynamic response to the antibody </plain></SENT>
<SENT sid="3" pm="."><plain>The initial 46% Â± 2.7% drop in SUV(max) of four target lesions correlated with a partial response by Response Evaluation Criteria in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">Solid Tumors</z:e> and a &gt;90% drop in serum carcinoembryonic antigen at 8 weeks, indicating that an early decrease in FDG uptake may predict subsequent clinical benefit in response to anti-EGFR antibody therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>